Rapt Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Nov 29, 2022

Click here to view more RAPT transcripts

Nov 29, 2022 / 01:00PM GMT
Ted Tenthoff - Piper Sandler - Analyst

My name is Ted Tenthoff, and I'm a Senior Biotechnology Analyst at Piper Sandler. It's wonderful to see you all in person and thank you for joining us for Piper Sandler's in-person Healthcare Conference.

Before I begin, I'm required to point out certain disclosures regarding the relationship between Piper and Rapt that are posted in the back of the room and also at the registration desk. Rapt is developing two distinct CCR4 antagonist: RPT193 for atopic dermatitis and other allergic conditions, and FLX475 for cancer.

Here with us today for Rapt is Brian Wong, CEO and President, and also Rodney Young, who is the CFO.

Thanks, guys for being with us.

Questions and Answers:

Ted Tenthoff - Piper Sandler - Analyst

So Brian, perhaps you can start off by describing the biology around CCR4 and how it plays a role both in cancer and in inflammation.

Brian Wong - RAPT Therapeutics - President & CEO

Yeah, great question. So CCR4 is the G-protein

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.